← back to search

Florian P. Maurer

University Medical Center Hamburg-Eppendorf · DE
Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include Tuberculosis Research and Epidemiology, Mycobacterium research and diagnosis, Antibiotic Resistance in Bacteria, and Infectious Diseases and Tuberculosis.
h-index
37
citations
3,727
works
150
NIH funding
primary concept
Medicine
email

Recent publications

The TB27 Transcriptomic Model for Predicting Mycobacterium tuberculosis Culture Conversion
Pathogens and Immunity 2025cited by 4position: middledoi
Impact of enhanced infection control and antimicrobial stewardship on infections by Clostridioides difficile, vancomycin-resistant enterococci, and third-generation cephalosporin-resistant Enterobacterales: a stepped-wedge cluster intervention study
Clinical Microbiology and Infection 2025cited by 2position: middledoi
Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance.
2024cited by 6position: contributordoi
Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland
Respiration 2024cited by 4position: middledoi
Molecular determinants of multidrug-resistant tuberculosis in Sierra Leone
Microbiology Spectrum 2024cited by 3position: middledoi
Impact of the COVID-19 pandemic on the real-world diagnostic infrastructure for tuberculosis—An ESGMYC collaborative study
PLoS ONE 2024cited by 2position: middledoi
Impact of the COVID-19 pandemic on the real-world diagnostic infrastructure for tuberculosis-An ESGMYC collaborative study.
2024cited by 1position: contributordoi
Nicht tuberkulöse Mykobakteriosen
Referenz Pneumologie 2024cited by 0position: contributordoi
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement
The Lancet Infectious Diseases 2023cited by 83position: middledoi
Towards clinical breakpoints for non-tuberculous mycobacteria – Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution
Clinical Microbiology and Infection 2023cited by 56position: middledoi
Therapie bei MDR-, prä-XDR-, XDR-Tuberkulose und Rifampicin-Resistenz oder bei Medikamentenunverträglichkeit gegenüber mindestens Rifampicin
Pneumologie 2023cited by 5position: middledoi
Minimum inhibitory concentrations and sequencing data have to be analysed in more detail to set provisional epidemiological cut-off values for <i>Mycobacterium tuberculosis</i> complex.
2023cited by 3position: contributordoi
Emergence of bedaquiline resistance in a high tuberculosis burden country.
2022cited by 91position: contributordoi
Ancient and recent differences in the intrinsic susceptibility of <i>Mycobacterium tuberculosis</i> complex to pretomanid
Journal of Antimicrobial Chemotherapy 2022cited by 66position: middledoi
Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study
The Lancet Microbe 2022cited by 49position: middledoi
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid.
2022cited by 45position: contributordoi
Rapid molecular diagnostics of tuberculosis resistance by targeted stool sequencing.
2022cited by 42position: contributordoi
Tuberkulose im Erwachsenenalter
Pneumologie 2022cited by 37position: middledoi
Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment
European Respiratory Journal 2022cited by 35position: middledoi
Origin and Global Expansion of <i>Mycobacterium tuberculosis</i> Complex Lineage 3.
2022cited by 27position: contributordoi
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
2022cited by 22position: contributordoi
Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment.
2022cited by 22position: contributordoi
One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk.
2022cited by 19position: contributordoi
Molecular Epidemiology of Mycobacterium abscessus Isolates Recovered from German Cystic Fibrosis Patients.
2022cited by 18position: contributordoi
Delineating Mycobacterium abscessus population structure and transmission employing high-resolution core genome multilocus sequence typing.
2022cited by 16position: contributordoi
C25-modified rifamycin derivatives with improved activity against <i>Mycobacterium abscessus</i>.
2022cited by 13position: contributordoi
Diagnostic Capacities for Multidrug-Resistant Tuberculosis in the World Health Organization European Region: Action is Needed by all Member States.
2022cited by 8position: contributordoi
The Use of Comparative Genomic Analysis for the Development of Subspecies-Specific PCR Assays for &lt;i&gt;Mycobacterium abscessus&lt;/i&gt;.
2022cited by 6position: contributordoi
Sub-Lineage Specific Phenolic Glycolipid Patterns in the <i>Mycobacterium tuberculosis</i> Complex Lineage 1.
2022cited by 6position: contributordoi
Integrated use of laboratory services for multiple infectious diseases in the WHO European Region during the COVID-19 pandemic and beyond.
2022cited by 6position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Stefan Niemann · University Hospital of Bern36 papers (2019–2024) · 34 papers (2019–2024)Matthias Merker · University Hospital Frankfurt23 papers (2019–2022)Christoph Lange · Médecins Sans Frontières18 papers (2019–2024)Katharina Kranzer · Hospital for Tropical Diseases15 papers (2019–2024)Thomas Kohl · German Center for Infection Research14 papers (2019–2022)Claudio U. Köser · Cambridge University Press12 papers (2019–2023)Jan Heyckendorf · Charité - Universitätsmedizin Berlin9 papers (2019–2024)Jakko van Ingen · Radboud University Nijmegen7 papers (2019–2024)Sönke Andres · London School of Hygiene & Tropical Medicine6 papers (2019–2024) · 5 papers (2019–2022)Laurent Kremer · Inserm5 papers (2019–2022)Ivan Barilar · German Center for Infection Research4 papers (2020–2024)Jan Rupp · University Medical Center Utrecht4 papers (2019–2025)Shaheed Vally Omar · National Institute for Communicable Diseases4 papers (2020–2022)Elvira Richter · London School of Hygiene & Tropical Medicine4 papers (2019–2024)Matt D. Johansen · University of Technology Sydney4 papers (2020–2022)Daniela Maria Cirillo · Medical Research Network4 papers (2019–2022) · 3 papers (2022–2024) · 3 papers (2022–2024)